Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?

Front Oncol · 2022 · PMC9195424 · PMID 35712487

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

failed to reach statistical significanceP = .058so close (0.05 < p ≤ 0.1)

In the PREOPANC trial, the resection rate was 62% in the NAT arm and 72% in the UFS arm; however, this finding failed to reach statistical significance (P = .058).

also in 6,035 other papers

failed to reach significanceno p-value reported

However, when analyzing from an ITT perspective, this result failed to reach significance (OR = 1.45, 95% CI = 0.91–2.30).

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.